



The European Agency for the Evaluation of Medicinal
Products
Veterinary Medicines and Information Technology

CVMP/VICH/546/00-FINAL
London, 30 July 2001

VICH Topic GL21

Step 7

EFFICACY OF ANTHELMINTICS: SPECIFIC RECOMMENDATIONS FOR POULTRY

TRANSMISSION TO CVMP	July 2000
TRANSMISSION TO INTERESTED PARTIES	July 2000
COMMENTS REQUESTED BEFORE	January 2001
FINAL APPROVAL OF CVMP	July 2001
DATE FOR COMING INTO OPERATION BY	July 2002

Public

7 Westferry Circus, Canary Wharf, London E14 4HB, UK

Tel (44 20) 74 18 8400 Fax (44 20) 74 18 84 47

E-mail: mail@emea.eudra.org <http://www.eudra.org/emea.html>

EMA 2001 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMA is acknowledged



VICH GL21 (ANTHELMINTICS: POULTRY – *GALLUS GALLUS*)

June 2001

For implementation at Step 7 - Draft 1

EFFICACY OF ANTHELMINTICS: SPECIFIC RECOMMENDATIONS FOR POULTRY - *GALLUS GALLUS*

Recommended for Implementation
on June 2001
by the VICH Steering Committee

THIS GUIDELINE HAS BEEN DEVELOPED BY THE APPROPRIATE VICH EXPERT WORKING GROUP AND WAS SUBJECT TO CONSULTATION BY THE PARTIES, IN ACCORDANCE WITH THE VICH PROCESS. AT STEP 7 OF THE PROCESS THE FINAL DRAFT IS RECOMMENDED FOR ADOPTION TO THE REGULATORY BODIES OF THE EUROPEAN UNION, JAPAN AND USA.

EFFICACY OF ANTHELMINTICS: SPECIFIC RECOMMENDATIONS FOR POULTRY - *GALLUS GALLUS*

INTRODUCTION

The present guideline for chickens (*Gallus gallus*) was developed by the Working Group established by the Veterinary International Cooperation on Harmonization (VICH), Anthelmintic Guidelines. It should be read in conjunction with the VICH Efficacy of Anthelmintic: General Requirements Guidelines (EAGR) which should be referred to for discussion of broad aspects for providing pivotal data to demonstrate product anthelmintic effectiveness. The present document is structured similarly to the EAGR with the aim of simplicity for readers comparing both documents.

This guideline for chickens is part of this EAGR and the aim is (1) to be more specific for certain specific issues for poultry not discussed in the EAGR; (2) to highlight differences with the EAGR on efficacy data requirements and (3) to give explanations for disparities with the EAGR. Although technical procedures to be followed are not the aim of this guideline, some details are given as until now the pertinent procedures have not been described elsewhere.

A. General Elements

1. The evaluation of effectiveness data

Only controlled tests based on parasite counts of adults/larvae are acceptable both for the dose determination and dose confirmation studies, since critical tests generally are not considered to be reliable for chickens. Egg counts with identification of the genus is the preferred method to evaluate the effectiveness in field studies. Adequate parasite infection should be defined in the protocol according to regional prevalence or historic and/or statistical data.

2. Use of natural or induced infections

Dose determination studies generally should be conducted using induced infections with either laboratory or recent field isolates.

Dose confirmation studies could be conducted using naturally infected birds which can have superimposed induced infections. This procedure will allow a wide range of parasites to be present in the experimental birds. Also induced infections in one of the studies is acceptable. Studies for larval stages should be conducted with induced infections only.

The history of the parasites used in the induced infection studies should be included in the final report.

3. Number of infective forms recommended for induced infections

Table 1 indicates the number of eggs/cysticercoids recommended to be used and will depend on the isolate that is used. The final number of eggs/cysticercoids used in the infection should be included in the final report.

Table 1. Range of infective stages used to produce adequate infections in chickens for anthelmintic evaluation.

Parasites	Range
<i>Ascaridia galli</i>	200-500
<i>Capillaria obsignata</i>	100-300
<i>Heterakis gallinarum</i>	200-300
<i>Raillietina cesticillus</i>	50-100
<i>Syngamus trachea</i>	200 - 600

Some factors to consider for induced infections in chickens are:

- a) Young birds should be used in the studies;
- b) To maximize the establishment of adequate infections it is recommended to use low numbers of infective stages;
- c) Stress (e.g. poor diets) is not required to generate helminth infections;
- d) Housing conditions should not allow accidental infections.

4. Recommendations for the calculation of effectiveness

4.1 Criteria to grant a claim

To be granted a claim, the following pivotal data should be included:

- a) Two dose confirmation studies conducted with a minimum of 6 adequately infected birds in each of the non-medicated group and the treated group;
- b) The differences in parasite counts between treated and control birds should be statistically significant ($p < 0.05$);
- c) Effectiveness should be 90% or higher calculated using transformed (geometric means) data of worm counts;
- d) The infection of the birds in the study will be deemed adequate based on historical, parasitological and/or statistical criteria.

4.2 Number of animals (dose determination and dose confirmation trials)

The minimum number of birds required per experimental group is a crucial point. Although the number of birds will depend on the possibility to process the data according to the adequate statistical analysis, it has been recommended, to achieve harmonization, that the inclusion of at least 6 birds in each experimental group is a minimum.

4.3 Adequacy of infection

Concerning the minimum adequate number of helminths, the decision will be made when the final report is submitted based on statistical and historical data, literature review, or expert testimony. The range of chicken helminths (adults) considered adequate to grant a claim will vary according to the species. Generally a mean number of 20 adult *A. galli* is considered to be adequate. Lower counts may be expected with *H. gallinarum*, *C. obsignata* and *R. cesticellus*. Necropsies should be conducted within 10 days of treatment.

4.4 Label claims

For adult claims, as a general rule, the treatment should not be administered earlier than 28 days after infection. It is recommended to include at least 6 sentinel birds for helminth characterization and quantification before treatment is initiated. For L4 claims, treatments should be given, as a general rule, 7 days after infection, except for *A. galli* and *H. gallinarum* which should be 16 days after infection.

5. Treatment procedures

The method of administration (oral, parenteral, topical, slow release etc.), formulation and extent of activity of a product will influence the protocol design.

When the drug is to be administered in the water or in a premix, it should be done as much as possible following the labelling recommendations. Palatability/consumption studies may be required for medicated premixes. Samples of medicated water or feed should be collected to confirm drug concentration. The amount of medicated product provided to each animal should be recorded to ensure that the treatment satisfies the label recommendations.

6. Bird selection, allocation and handling

Test birds should be clinically healthy and representative of the age, sex, and class for which the claim of the test anthelmintic is to be made. In general, birds should be young and from a breed that is susceptible to helminth infections. Birds should be randomly assigned to each group. Blocking in replicates by weight, sex, age, and/or exposure to parasites may aid in reducing trial variance. Faecal egg counts are also acceptable to allocate the experimental birds. Control birds must be of the same weight, age, breed, sex and history as the treated group. For induced infections, the use of helminth naive birds is recommended.

Animal housing, feeding and care should follow strict requirements of welfare, including vaccination according to local practices. This information should be provided in the final report. A minimum 10-day acclimatisation period is recommended. Housing and feed/water should be adequate according to the geographical location. Birds should be monitored daily to determine adverse reactions.

B. Specific Evaluation Studies

1. Dose determination studies

If the treatment requires extended administration, one or more studies are required to determine the minimum treatment period for efficacy.

2. Dose confirmation

No species specific recommendations.

3. Field efficacy studies

Due to commercial constraints the experimental unit in these studies invariably will be the shed/house. A shed/house can receive only one treatment, i.e. control or medicated.

Clinical observations, production variables, and records of mortality should be maintained and compared to historical data of the commercial establishment. Slaughterhouse inspection reports should be included in the final report, when the number of test animals can not be confirmed.